Accepted for Publication: August 21, 2011.
Author Contributions: Ms Wan and Dr Gelfand had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Abuabara, Van Voorhees, Bebo, Krueger, Callis Duffin, and Gelfand. Acquisition of data: Abuabara, Shin, Krueger, and Gelfand. Analysis and interpretation of data: Wan, Troxel, Shin, and Gelfand. Drafting of the manuscript: Wan. Critical revision of the manuscript for important intellectual content: Wan, Abuabara, Troxel, Shin, Van Voorhees, Bebo, Krueger, Callis Duffin, and Gelfand. Statistical analysis: Wan, Troxel, Shin, and Gelfand. Obtained funding: Krueger and Gelfand. Administrative, technical, and material support: Wan, Abuabara, Shin, Bebo, Krueger, and Gelfand. Study supervision: Gelfand.
Financial Disclosure: Dr Van Voorhees served on the advisory board of and was an investigator and speaker for Amgen and Genentech, receiving honoraria and grants; she was a consultant for Incyte, Leo, VGX, and Xtrac, receiving honoraria; she served on the advisory board and was a speaker for Abbott, Centocor, and Connetics, receiving honoraria; she served on the advisory board and was an investigator for Bristol-Myers Squibb and Warner Chilcott, receiving honoraria and grants; she was an investigator for Astellas, IDEC, and Roche, receiving grants; she served as a consultant for Amgen; and she received honoraria from Synta. Dr Bebo has had relationships with Abbott, Amgen, Astellas, Centocor, Galderma, Genentech, PhotoMedix, Stiefel/GSK, Warner Chilcott, and Wyeth, receiving other benefits. Dr Krueger served on the steering committees for Centocor/Phoenix 2 and Golimumab/psoriatic arthritis, receiving no compensation; he served on the steering committee for PSOLAR, receiving other financial benefit; he served on the data monitoring board for Novartis and as chair of the data-monitoring safety board for Pfizer, receiving other financial benefit; was a consultant and/or advisory board member for Abbott, Almirall, Amgen, Anacor, Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Centocor, CombinatoRx, Genzyme, Isis, Lilly, L’Oreal, Lupin Limited, MedaCorp, Medicis, Novartis, Novo Nordisk, Pfizer, Schering-Plough, Somagenics, theDerm.org, Synvista, Warner Chilcott, UCB, Vascular Biogenics Limited, and ZARS, receiving honoraria or other financial benefit; he was a stockholder in ZARS, receiving stock options; he was a speaker for Abbott, Amgen, Astellas, Centocor, and the National Psoriasis Foundation, receiving honoraria; and he was an investigator for Abbott, Amgen, and Centocor, receiving grants. Dr Callis Duffin was an investigator, consultant, and speaker for Abbott, Amgen, and Centocor, receiving honoraria and salary; she served on the advisory board of Amgen; and received residency/fellowship program funding from Abbott and Amgen. Dr Gelfand served as consultant and investigator with Abbott, Amgen, Centocor, Genentech, Novartis, and Pfizer, receiving grants and honoraria; he was a consultant with Celgene, Covance, Galderma, Shire Pharmaceuticals, and Wyeth, receiving honoraria; and he was an investigator with Shionogi, receiving grants.
Funding/Support: This study was supported by grant RC1-AR058204 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Dr Gelfand), Training Grant T32-AR07465 from the National Institutes of Health (Ms Wan and Mr Shin), and the Doris Duke Clinical Research Fellowship (Dr Abuabara).
Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.